Vogt-Koyanagi-Harada Disease Associated with COVID-19 mRNA Vaccine

Ocul Immunol Inflamm. 2021 Aug 18;29(6):1212-1215. doi: 10.1080/09273948.2021.1974492. Epub 2021 Sep 10.

Abstract

A 54-year-old Chinese male with no previous ocular history presented to the ophthalmology department for the bilateral acute painless blurring of vision after receiving the 1st dose of COVID-19 mRNA vaccine (PFIZER-BioNTech/COMIRNATY). Clinical examination and imaging tests were consistent with Vogt-Koyanagi-Hara disease. The patient responded well with a high dose of intravenous methylprednisolone followed by a tapering dose of oral prednisolone.

Keywords: COVID-19 vaccine; PfizerBioNtech; VKH disease; exudative retinal detachment; vaccine side effects.

Publication types

  • Case Reports

MeSH terms

  • Autoimmunity
  • BNT162 Vaccine / adverse effects*
  • COVID-19 / prevention & control*
  • Fluorescein Angiography
  • Glucocorticoids / therapeutic use
  • Humans
  • Male
  • Methylprednisolone / therapeutic use
  • Middle Aged
  • Pulse Therapy, Drug
  • SARS-CoV-2*
  • Tomography, Optical Coherence
  • Uveomeningoencephalitic Syndrome / diagnosis
  • Uveomeningoencephalitic Syndrome / drug therapy
  • Uveomeningoencephalitic Syndrome / etiology*
  • Vaccination / adverse effects*

Substances

  • Glucocorticoids
  • BNT162 Vaccine
  • Methylprednisolone